SCHEMBL2289939

SCHEMBL2289939

C[C@H](CCC(=O)OC(C)(C)C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@@H](N)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.68
▸ MEN1 O00255 2/20 0.68
▸ KMT2A Q03164 2/20 0.68
▸ USP2 O75604 2/20 0.68
▸ LMNA P02545 1/20 0.68
▸ MAPK1 P28482 1/20 0.68
▸ GPBAR1 Q8TDU6 5/20 0.63
▸ SLC10A2 Q12908 2/20 0.63
▸ NR1H4 Q96RI1 2/20 0.63
▸ TBXA2R P21731 1/20 0.63
▸ PDE3A Q14432 1/20 0.63
▸ CA1 P00915 7/20 0.56
▸ CA2 P00918 7/20 0.56
▸ ABCC4 O15439 1/20 0.54
▸ CYP2C9 P11712 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ VDR P11473 1/20 0.52
▸ CYP3A4 P08684 2/20 0.51
▸ SLCO1B3 Q9NPD5 1/20 0.51
▸ SLCO1B1 Q9Y6L6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8736941 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL133225 0.91 MAPT (0.81) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL14188114 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL13014309 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL5031235 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL5032855 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL20079324 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL14570878 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL15289542 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA
SCHEMBL19313971 0.90 MAPT (0.83) MAPTMEN1KMT2AUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989417-B2 Linkers for radiopharmaceutical compounds BRACCO IMAGING S.P.A. (IT) 2011-08-02 — — US disclosed
EP-1583564-B1 IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS BRACCO IMAGING SPA (IT) 2009-07-01 — — EP disclosed
EP-1583564-A4 IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS BRACCO IMAGING SPA (IT) 2007-06-13 — — EP disclosed
US-20060241018-A1 Linkers for radiopharmaceutical compounds BRACCO IMAGING S.P.A. (IT) 2006-10-26 — — US disclosed
EP-1583564-A2 IMPROVED LINKERS FOR PHARMACEUTICAL COMPOUNDS Bracco Imaging, S.P.A. (IT) 2005-10-12 — — EP disclosed
WO-2004062574-A9 IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS BRACCO IMAGING SPA (IT) 2005-05-26 — — WO disclosed
WO-2004062574-A2 IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS BRACCO IMAGING S.P.A. (IT) 2004-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241018-A1 Linkers for radiopharmaceutical compounds VIP, QPCT, NPPA MAPT 2998/4885MEN1 15/4885KMT2A 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback